The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond
- PMID: 26116527
- DOI: 10.1016/j.cgh.2015.06.017
The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond
Abstract
Drug-induced liver injury (DILI) remains a leading reason why new compounds are dropped from further study or are the subject of product warnings and regulatory actions. Hy's Law of drug-induced hepatocellular jaundice causing a case-fatality rate or need for transplant of 10% or higher has been validated in several large national registries, including the ongoing, prospective U.S. Drug-Induced Liver Injury Network. It serves as the basis for stopping rules in clinical trials and in clinical practice. Because DILI can mimic all known causes of acute and chronic liver disease, establishing causality can be difficult. Histopathologic findings are often nonspecific and rarely, if ever, considered pathognomonic. A daily drug dose >50-100 mg is more likely to be hepatotoxic than does <10 mg, especially if the compound is highly lipophilic or undergoes extensive hepatic metabolism. The quest for a predictive biomarker to replace alanine aminotransferase is ongoing. Markers of necrosis and apoptosis such as microRNA-122 and keratin 18 may prove useful in identifying patients at risk for severe injury when they initially present with a suspected acetaminophen overdose. Although a number of drugs causing idiosyncratic DILI have HLA associations that may allow for pre-prescription testing to prevent hepatotoxicity, the cost and relatively low frequency of injury among affected patients limit the current usefulness of such genome-wide association studies. Alanine aminotransferase monitoring is often recommended but has rarely been shown to be an effective method to prevent serious DILI. Guidelines on the diagnosis and management of DILI have recently been published, although specific therapies remain limited. The LiverTox Web site has been introduced as an interactive online virtual textbook that makes the latest information on more than 650 agents available to clinicians, regulators, and drug developers alike.
Keywords: DILI; Drug-induced Liver Injury; Hepatotoxicity.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials.Exp Biol Med (Maywood). 2018 Feb;243(3):300-307. doi: 10.1177/1535370217740853. Epub 2017 Nov 2. Exp Biol Med (Maywood). 2018. PMID: 29096561 Free PMC article. Review.
-
Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.Gastroenterology. 2014 Jul;147(1):109-118.e5. doi: 10.1053/j.gastro.2014.03.050. Epub 2014 Apr 1. Gastroenterology. 2014. PMID: 24704526
-
DILI and drug development: a regulatory perspective.Semin Liver Dis. 2014 May;34(2):215-26. doi: 10.1055/s-0034-1375961. Epub 2014 May 31. Semin Liver Dis. 2014. PMID: 24879985 Review.
-
Predicting and preventing acute drug-induced liver injury: what's new in 2010?Expert Opin Drug Metab Toxicol. 2010 Sep;6(9):1047-61. doi: 10.1517/17425255.2010.503706. Expert Opin Drug Metab Toxicol. 2010. PMID: 20615079 Review.
-
Drug-induced liver injury.Mayo Clin Proc. 2014 Jan;89(1):95-106. doi: 10.1016/j.mayocp.2013.09.016. Mayo Clin Proc. 2014. PMID: 24388027 Review.
Cited by
-
Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?Int J Mol Sci. 2017 Apr 11;18(4):803. doi: 10.3390/ijms18040803. Int J Mol Sci. 2017. PMID: 28398242 Free PMC article. Review.
-
Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone.Int J Clin Pharm. 2018 Aug;40(4):911-920. doi: 10.1007/s11096-018-0698-5. Epub 2018 Jul 26. Int J Clin Pharm. 2018. PMID: 30051228
-
Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial.Hepatology. 2017 Dec;66(6):1727-1738. doi: 10.1002/hep.29306. Epub 2017 Oct 30. Hepatology. 2017. PMID: 28586116 Free PMC article. Clinical Trial.
-
Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature.Drug Saf. 2016 Sep;39(9):801-21. doi: 10.1007/s40264-016-0427-8. Drug Saf. 2016. PMID: 27142208 Review.
-
Knowledge Mapping of Drug-Induced Liver Injury: A Scientometric Investigation (2010-2019).Front Pharmacol. 2020 Jun 5;11:842. doi: 10.3389/fphar.2020.00842. eCollection 2020. Front Pharmacol. 2020. PMID: 32581801 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials